Gopalakrishna Harish, Mironova Maria, Dahari Harel, Koh Christopher, Heller Theo
Liver Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
Curr Hepatol Rep. 2024;23(1):32-44. doi: 10.1007/s11901-024-00643-w. Epub 2024 Feb 1.
Hepatitis D Virus (HDV), although a small defective virus, poses a substantial public health challenge due to lack of awareness, underrecognized prevalence, and limited treatment options. Universal HDV screening within hepatitis B virus (HBV) cohorts is essential to address this issue. Despite its aggressive nature, effective HDV therapies have remained elusive for over four decades.
Advances in understanding HDV's biology and clinical behavior offer potential therapeutic breakthroughs, fostering optimism. As insights grow, effective and targeted therapies are being developed to improve HDV management.
This review delves into HDV's intricate structure and biology, highlighting formidable hurdles in antiviral development. It emphasizes the importance of widespread screening, exploring noninvasive diagnostics, and examining current and emerging innovative therapeutic strategies. Moreover, the review explores models for monitoring treatment response. In essence, this review simplifies the complexities of effectively combating HDV.
丁型肝炎病毒(HDV)虽是一种小型缺陷病毒,但由于认识不足、流行率未得到充分认识以及治疗选择有限,对公共卫生构成了重大挑战。在乙型肝炎病毒(HBV)队列中进行普遍的HDV筛查对于解决这一问题至关重要。尽管HDV具有侵袭性,但四十多年来一直难以找到有效的治疗方法。
在了解HDV生物学特性和临床行为方面取得的进展带来了潜在的治疗突破,令人感到乐观。随着认识的不断深入,正在开发有效且有针对性的疗法以改善HDV的管理。
本综述深入探讨了HDV复杂的结构和生物学特性,突出了抗病毒研发中面临的巨大障碍。强调了广泛筛查、探索非侵入性诊断方法以及研究当前和新兴创新治疗策略的重要性。此外,该综述还探讨了监测治疗反应的模型。本质上,本综述简化了有效对抗HDV的复杂性。